Introduction
Absence seizures, characterized by frequent brief staring episodes, are commonly encountered in a number of pediatric idiopathic generalized epilepsy syndromes including childhood and juvenile absence epilepsies (CAE, JAE), and juvenile myoclonic epilepsy. Usually, CAE and JAE are considered benign, drug responsive, age-limited entities. However, up to 20% of patients may not achieve seizure remission with adequate drug therapy. 1 In the landmark CAE study, the freedom-from-failure rates were 53% and 58%, respectively for ethosuximide and valproic acid, after 16 weeks of therapy. 2 Thus, a proportion of patients with these syndromes may qualify as having drug resistant epilepsy by International League Against Epilepsy (ILAE) definition. 3 Further, approximately 10% of patients with CAE and 24% with JAE do not experience age related remission. 4 There is markedly limited information about management of such patients with medically refractory absence epilepsies. In a recent series of 12 patients, 6 (50%) had >90% seizure reduction at 12 months of treatment with amantadine. 5 However, in this study, 3 patients discontinued amantadine within 6 months due to lack of efficacy. Three additional patients reported significant adverse effects including behavioral changes, headache, dizziness and weight loss. 5 There have been 2 earlier isolated uncontrolled reports of use of amantadine for absence seizures unresponsive to usual AED. 6, 7 Besides these studies, there is paucity of evidence for efficacy of other treatment options for children with medically refractory absence epilepsies. These epilepsies have primarily generalized ictal onset and these patients are not usually thought to be candidates for resective epilepsy surgery. However, vagus nerve stimulation (VNS) has been tried in adults with medically refractory generalized epilepsies including patients with absence seizures. In a series of 12 patients, 58% decrease in frequency of absence seizures was noted after a mean follow-up of 23 months. 8 In some other reports of use of VNS for treatment of adults with medically refractory generalized epilepsy, the outcome for absence seizures Seizure 22 (2013) was not presented. 9, 10 In view of this evidence gap, particularly in children, this case series is reported to estimate the efficacy of VNS in patients with medically refractory absence epilepsy.
Methods
Patients were identified by a retrospective chart review of all VNS device recipients between January 1, 2006 and December 31, 2011. The lower cut-off date was chosen because electronic medical records (EMR) system was installed at that time ensuring uniformity of information and ease of access. Additionally, since then all the VNS device insertions were performed by a single neurosurgeon (FTM). All patients diagnosed with absence epilepsy based on clinical features, EEG findings and a normal MRI of the brain, were eligible for inclusion if they received a VNS during the study period. Specifically, the diagnosis of CAE/JAE was based on ILAE revised classification of epilepsy syndromes, including frequent clinical absence seizures and characteristic EEG pattern.
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The extracted data comprised of demographic variables including age, sex, age at onset of seizures, duration of epilepsy prior to VNS implant, age at VNS implant; and, clinical details including daily seizure frequency, seizure types in addition to absence seizures, developmental delay or intellectual disability, epilepsy syndrome, and failed AED including those at referral. Both initial and follow-up seizure frequencies obtained from EMR charts were based on parental reporting. The outcome measures included reduction in daily seizure frequency measured as a percentage of pre-VNS seizure frequency and classified on ILAE outcome scale. 12 Lengths of follow-up and technical complications related to VNS device were also noted. EEG outcome was obtained from reports available in EMR for routine EEG. It was classified as improved, unchanged or worse based on frequency and duration of spikewave bursts, and, presence, number and duration of electrographic or electro-clinical seizures. The data was recorded in an Excel (Microsoft Corp., Redmond, WA) spreadsheet. Appropriate summary statistics were calculated for all variables.
Neurocybernetic prosthesis (NCP) system (Cyberonics Inc., Houston, TX), implanted with standard surgical technique was used for left vagus nerve stimulation. 13, 14 The device was switched on in immediate post-operative period with the following settings: current 0.25 mA, frequency 20-30 Hz, pulse width 250-500 ms, on time 30 s, off time 5 min. At follow-up visits every 1-3 months, the current was gradually increased by 0.25 mA until patient tolerance, seizure freedom or a maximum of 2.5 mA was achieved. The magnet output current was always programmed to be 0.25-0.5 mA higher than automatic stimulation, with a pulse width of 500 ms for a period of 60 s. Changes in concurrent anti-seizure medications or the decision to go for ''rapid cycling'', were at the discretion of treating neurologist.
Results
A total of 9 patients (7 males) with a mean age of 14.2 years (AE5.7) were found, with mean age of seizure onset of 5.4 years (AE3.9). The mean duration of epilepsy prior to VNS implant in these patients was 3.9 years (AE1.4), with the mean age at VNS implantation being 10.8 years (AE5.6). Clinically, 7 of the patients were classified as having CAE and 2 as JAE. The median seizure frequency based on parental reporting was found to be 25/day (inter-quartile range 61). Although 3 of the patients had generalized tonic-clonic seizures (GTCS) in addition to absence seizures, only 1 had a past history of status epilepticus. Two of the patients had borderline to mild developmental delay or intellectual disability. Prior to surgical referral, these patients had failed 3-21 AED (median = 5, Table 1 ). Three patients had functional neuroimaging as a part of their pre-surgical evaluation, which showed discordant data among different modalities.
These patients had follow-up for a mean duration of 33.9 months (AE25.5, minimum 4 months). One patient attained complete seizure freedom (ILAE class 1), 6 had ILAE class 4 and 2 had class 5 outcomes, respectively. Mean reduction in daily seizure frequency was observed to be 53.5 AE 60.3% (1-sided p-value for paired ttest = 0.04), with 5 patients (55.6%) having a reduction of !50%. Only 1 patient had increased seizure frequency after a follow-up of 26 months (Table 1) . EEG improved in 4 (44.4%) patients, with complete normalization in 1 (patient with complete seizure remission). It was classified as unchanged in 4 (44.4%) other patients, though on subjective review there was reduction in frequency of spike-wave bursts. One patient showed worsening of EEG with deterioration of background rhythm (patient with increased seizure frequency, Table 1 ). Two patients (22.2%) had lead fractures as a device related adverse event and the hardware needed to be replaced.
Discussion
This case series provides preliminary evidence for efficacy of VNS in children with medically refractory absence epilepsy, with 54% mean reduction in daily seizure frequency and a 50% responder rate of 56%, after a mean follow-up of about 3 years. The EEG outcome showed agreement with clinical response (Table 1) . Our observations broadly agree with previously published experience with VNS in refractory idiopathic generalized epilepsy (IGE). In the E04 cohort, there was 60% reduction in mixed seizure burden in 7 patients with 9 This difference in efficacy probably results from heterogeneity of patient populations, especially in ages of onset of seizures ( Table 2 ). The proportion of patients experiencing !50% reduction in seizure frequency was found to be 56%. This figure is also comparable to other studies, as for mixed seizure types, 50% responder rate has varied from 44% to 67% (Table 2) . Although stimulation related adverse effects have been commonly documented, there is limited reporting of device related complications. In our series, 2 patients had lead fractures suspected initially due to abnormally high impedance. In a larger (n = 105) study looking at operative and technical complications with VNS, lead fracture was noted to be the most frequent technical complication (7.6%). 16 More interestingly, the hardware failure was observed exclusively in children. 16 The present study has some inadvertent limitations. As in any retrospective review, the observed decrease in seizure burden cannot be attributed to VNS causally, as changes in drug therapy and variation in device settings are important confounding factors. Secondly, regarding ascertainment of seizure burden, we relied on parental reporting as documented in EMR. While recognized to be imperfect, 17 this was the best available measure to us. Some of the other investigators have used better methods to quantify seizure frequency e.g. in the E04 cohort, a baseline period of video-EEG monitoring was used. 15 This was not feasible for us. Finally, we have reported the decrease in mixed seizure burden and not separately for absence seizures. However, we believe that it is unlikely to distort clinical interpretation, since only 3 patients had GTCS and the frequency was much less than absence seizures. Two patients in our study had onset before 2 years of age and mild developmental delay. The diagnosis of CAE can be challenged in these patients, though they had typical absence seizures and characteristic EEG pattern. Regarding cognitive problems in these 2 patients, multiple AED and high seizure burden could have been potentially contributory factors. However, the combination of atypical features like early onset and intellectual disability should prompt further evaluation for etiology, since absence seizures have been recognized as a clinical feature in some specific disorders including recently in GLUT1 deficiency. 18 Conventionally, CAE and JAE are regarded as pharmacotherapy responsive, age-limited syndromes. However, approximately 10% of patients with CAE do not have spontaneous remission. 4 In a Swedish population-based study, a 91% remission rate was observed in CAE patients with only absence seizures. 19 Other studies have suggested that up to 6% of patients with CAE, can have persistent absence seizures even in middle and late adulthood. 4 Further, up to 60% of patients with onset of typical absence seizures in childhood have later onset GTCS in addition. 4, 20, 21 Hence, remission of only absence seizures may not mean complete seizure freedom. In JAE especially with 10 or more GTCS, up to 24% may not achieve remission, though the prognosis is better in those with only absence seizures or rare GTCS. 4, 22 These figures represent conservative estimates based on strict case definitions. 4 In practice, children with IGE syndromes present with considerable variation and overlapping features. This group is particularly likely to have a proportion of patients at risk for medical intractability. Unfortunately, there is remarkable paucity of systematic evidence for therapeutic options in such patients. Hence, we believe that the findings generated in this report are clinically important because it included relatively homogenous patient population with absence epilepsies and had a longer average follow-up as compared to previous data (Table 2 ). Based on limited evidence, VNS may be considered as a treatment option in patients with medically refractory absence epilepsy, where spontaneous remission appears unlikely based on clinical course.
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